术前左西孟旦治疗减少左心室辅助装置植入患者术后右心衰竭
该研究回顾性分析2010年11月至2019年12月在本中心因终末期心力衰竭行左心室辅助装置(LVAD)植入的224例连续患者,其中117例(52.2%)在LVAD植入前7天内接受静脉左西孟旦治疗。结果显示术前左西孟旦治疗显著降低术后右心衰竭(RV-F)风险,尤其术前右心室功能正常的患者,但增加术后血管活性肌力评分,对住院、30天及5年死亡率无显著影响。
要点
- 术前左西孟旦治疗显著降低LVAD植入术后右心衰竭风险,尤其术前右心室功能正常者。
- 左西孟旦组术后24小时血管活性肌力评分显著升高。
- 住院、30天及5年死亡率两组无显著差异。
核心结论
- 术前左西孟旦治疗降低LVAD植入术后右心衰竭风险,尤其术前右心室功能正常者,对LVAD植入后长达5年的死亡率无影响。
研究设计与样本
- 回顾性分析2010年11月至2019年12月在本中心因终末期心力衰竭行LVAD植入的224例连续患者,其中117例(52.2%)在LVAD植入前7天内接受静脉左西孟旦治疗(左西孟旦组)。
主要发现
- 住院死亡率左西孟旦组18.8% vs 对照组23.4%,P=0.40;30天死亡率左西孟旦组12.0% vs 对照组14.0%,P=0.65;5年死亡率两组相当。
- 多因素分析显示术前左西孟旦治疗显著降低术后右心衰竭(比值比2.153,置信区间1.146-4.047,P=0.017),但增加术后血管活性肌力评分(术后24小时:比值比1.023,置信区间1.008-1.038,P=0.002)。
- 经1:1倾向性评分匹配每组74例后,上述结果进一步得到证实。
- 术前右心室功能正常亚组中,左西孟旦组术后右心衰竭发生率显著低于对照组(17.6% vs 31.1%,P=0.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Perioperative mortality and complications still remain high after left ventricular assist device (LVAD) implantation, especially in highly compromised patient cohorts. Here, we evaluate the effects of preoperative Levosimendan therapy on peri- and postoperative outcomes after LVAD implantation. METHODS: We retrospectively analysed 224 consecutive patients with LVAD implantation for end-stage heart failure between November 2010 and December 2019 in our centre with regard to short- and longer-term mortality as well as incidence of postoperative right ventricular failure (RV-F). Out of these, 117 (52.2%) received preoperative i.v. Levosimendan therapy within 7 days before LVAD implantation (Levo group). RESULTS: In-hospital, 30-day and 5-year mortality was comparable (in-hospital mortality: 18.8% vs 23.4%, P = 0.40; 30-day mortality: 12.0% vs 14.0%, P = 0.65; Levo vs control group). However, in the multivariate analysis, preoperative Levosimendan therapy significantly reduced postoperative RV-F but increased postoperative vasoactive inotropic score ([RV-F: odds ratio 2.153, confidence interval 1.146-4.047, P = 0.017; vasoactive inotropic score 24 h post-surgery: odds ratio 1.023, confidence interval 1.008-1.038, P = 0.002). These results were further confirmed by 1:1 propensity score matching of 74 patients in each group. Especially in the subgroup of patients with normal preoperative RV function, the prevalence of postoperative RV-F was significantly lower in the Levo- group as compared to the control group (17.6% vs 31.1%, P = 0.03; respectively). CONCLUSIONS: Preoperative Levosimendan therapy reduces the risk of postoperative RV-F, especially in patients with normal preoperative RV function without effects on mortality up to 5 years after LVAD implantation.
引用
- Sugimura Y, Kalampokas N, Arikan M, et al. Preoperative Levosimendan therapy reduces postoperative right ventricular failure in patients undergoing left ventricular assist device implantation. Interdiscip Cardiovasc Thorac Surg. 2023. PMID: 36802258. doi:10.1093/icvts/ivac289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。